Literature DB >> 7911242

Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.

M J Scanlan1, B K Raj, B Calvo, P Garin-Chesa, M P Sanz-Moncasi, J H Healey, L J Old, W J Rettig.   

Abstract

The human fibroblast activation protein alpha (FAP alpha) is a M(r) 95,000 cell surface antigen selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. Normal adult tissues are generally FAP alpha-, but some fetal mesenchymal tissues transiently express the molecule. Because of its restricted normal tissue distribution and abundant expression in the stroma of over 90% of breast, colorectal, and lung carcinomas, FAP alpha is under clinical evaluation as a target for immunodetection and immunotherapy of epithelial cancers. In the present study, we have isolated a full-length cDNA for FAP alpha through expression cloning in COS-1 cells. The FAP alpha cDNA codes for a type II integral membrane protein with a large extracellular domain, transmembrane segment, and short cytoplasmic tail. FAP alpha shows 48% amino acid sequence identity to the T-cell activation antigen CD26, a membrane-bound protein with dipeptidyl peptidase IV (DPPIV) activity; however, unlike FAP alpha, CD26 is widely expressed in normal tissues. Three catalytic domains shared by DPPIV homologues in different species and by other serine proteases are conserved in FAP alpha. Immunochemical analysis of COS-1 cells coexpressing FAP alpha and CD26 revealed that the two molecules form heteromeric cell surface complexes, suggesting that a previously identified FAP alpha-associated M(r) 105,000 protein of cultured fibroblasts and growth factor-stimulated melanocytes, FAP beta, is identical to CD26. In vivo coexpression of FAP alpha and CD26 is found in reactive fibroblasts of healing wounds but not in tumor stromal fibroblasts or sarcomas (FAP alpha +/CD26-). The putative serine protease activity of FAP alpha and its in vivo induction pattern may indicate a role for this molecule in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911242      PMCID: PMC44055          DOI: 10.1073/pnas.91.12.5657

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family.

Authors:  K Wada; N Yokotani; C Hunter; K Doi; R J Wenthold; S Shimasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

2.  CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.

Authors:  M A Shipp; G E Tarr; C Y Chen; S N Switzer; L B Hersh; H Stein; M E Sunday; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

4.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Authors:  P Garin-Chesa; L J Old; W J Rettig
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Non-conservation of a catalytic residue in a dipeptidyl aminopeptidase IV-related protein encoded by a gene on human chromosome 7.

Authors:  N Yokotani; K Doi; R J Wenthold; K Wada
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

6.  Direct association of adenosine deaminase with a T cell activation antigen, CD26.

Authors:  J Kameoka; T Tanaka; Y Nojima; S F Schlossman; C Morimoto
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

7.  Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.

Authors:  W J Rettig; P Garin-Chesa; J H Healey; S L Su; H L Ozer; M Schwab; A P Albino; L J Old
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

8.  Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.

Authors:  W J Rettig; P Garin-Chesa; H R Beresford; H F Oettgen; M R Melamed; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins.

Authors:  R Ueda; S Ogata; D M Morrissey; C L Finstad; J Szkudlarek; W F Whitmore; H F Oettgen; K O Lloyd; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

10.  Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.

Authors:  B Seed; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

View more
  153 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

3.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

Authors:  Markus Loeffler; Jörg A Krüger; Andreas G Niethammer; Ralph A Reisfeld
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

4.  Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.

Authors:  Aaron M LeBeau; W Nathaniel Brennen; Saurabh Aggarwal; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

Review 5.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

6.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

7.  Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine interleukin-1 loop.

Authors:  Daniela Kessler-Becker; Thomas Krieg; Beate Eckes
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

8.  Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Damanzoopinder Samrao; Grace Kim; Kate Lawrenson; Teodulo Meneses; Song Liu; Annie Yessaian; Tanja Pejovic
Journal:  Cancer Microenviron       Date:  2013-11-10

9.  RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia.

Authors:  David J Shields; Sherry Niessen; Eric A Murphy; Ainhoa Mielgo; Jay S Desgrosellier; Steven K M Lau; Leo A Barnes; Jacqueline Lesperance; Michael Bouvet; David Tarin; Benjamin F Cravatt; David A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

10.  Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells.

Authors:  Alanna Kennedy; Huan Dong; Donghai Chen; Wen-Tien Chen
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.